LEXISCAN

NDC 0469-6501 · Astellas Pharma US, Inc.

Generic nameregadenoson

Dosage formINJECTION, SOLUTION

RouteINTRAVENOUS

Active ingredient(s)REGADENOSON

Strength.08 mg/mL

Pharmacologic classAdenosine Receptor Agonist [EPC], Adenosine Receptor Agonists [MoA]

Marketing categoryNDA

Packages

0469-6501-89 — 5 mL in 1 SYRINGE, PLASTIC (0469-6501-89)

Billed under HCPCS

J2785 — Injection, regadenoson, 0.1 mg Medicare Part B payment limit (ASP + 6%): $2.51

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

10135-803 — Regadenoson, 16729-477 — REGADENOSON, 36000-364 — regadenoson, 51662-1448 — LEXISCAN(R) (REGADENOSON), 55150-443 — regadenoson, 60505-6116 — regadenoson, 60505-6288 — regadenoson, 68083-175 — Regadenoson, 71288-201 — Regadenoson, 83032-001 — Regadenoson, 85742-012 — Regadenoson

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q4 (October 2026 release). All data sources · How to read the labels

Current data releases:ICD-10-CM FY2027 · ICD-10-PCS FY2027 · HCPCS October 2026 · MS-DRG v44 · Medicare Code Editor v44.0 · NCCI PTP Q4 2026 · MUE Q4 2026 · NCD code lists 2026-01 · LCD export September 28, 2026 · All releases and sources